The major US equity indices have now dropped for three weeks. Amidst this, last Friday’s action should bode well for the bulls – at least in the near term.
Investor attention is now on whether Merck will confirm a formal offer as speculation over a potential acquisition continues dominating discussions around the stock.
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQTSLA) and Palantir Technologies, Inc.
Non-commercials just switched to net long e-mini S&P 500 futures after remaining net short for 14 weeks in a row. They are likely to do well on this switch – at least near term.
In this video lesson I review the day-one of a new rally attempt in the overall market, discuss my new swing trade in a cyber-security leader, and review my tier-one long-term portfolio purchases in my favorite leading stocks before the closing bell.
All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024.
The company expects its current cash position and retained portions of payments from its agreement with Vertex to support operations into the second quarter of 2027.
All three major indices remain in the red midday Thursday, after trimming earlier losses which saw the Dow Jones down more than 600 points at session lows. The major averages lost more than 2% this week as U.S.
There was some modest buying today from the open, but volume was light and markets are below trading range support established during the latter part of 2024.
The health agency has accepted Capricor's Biologics License Application for full approval of deramiocel as a treatment for Duchenne muscular dystrophy cardiomyopathy.
